Mucormycosis following COVID19: clinical case and literature review | CMAC

Mucormycosis following COVID19: clinical case and literature review

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):255-262

Type
Review

Abstract

Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).

Views
0 Abstract
0 PDF
0 Crossref citations
Shared